EE343 Cost-Effectiveness Analysis of Resmetirom for the Treatment of Adults With Noncirrhotic NASH and Moderate-to-Advanced Liver Fibrosis in the US: Integrating the Dual NASH Resolution and Fibrosis Improvement Endpoints
Abstract
Authors
Y Kim Z Smith D Mitchell S Johnson